drugset / Trial / NCT01005823

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

NCT01005823

Phase 1 Completed 36 enrolled LEO Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with LEO 29102 in adult patients with atopic dermatitis.

Timeline

Start
2009-10
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator LEO 29102 Unknown 0.3 unknown Topical
Comparator LEO 29102 Unknown 1 unknown Topical
Comparator LEO 29102 Unknown 2.5 unknown Topical

Indications